CONTENTS

Japanese Journal of Clinical Pharmacology and Therapeutics

Vol.43 No.2 March 2012

Special Articles
Current Status and Defect on the Development of DDS Preparations
Kanji TAKADA 51

Original
Investigation of Bioequivalence between MSG203 and Paxil® (Paroxetine Hydrochloride Hydrate) after Single Oral Administration in Japanese Healthy Male Subjects:
Detailed Study in Different CYP2D6 Phenotypes
Naoki UCHIDA, et al. 57

Forum
Psychological Analysis of Parents Whose Children Participated in Pediatric Clinical Trials
Shigehiro UEYAMA, et al. 65

Report
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1
Harumasa NAKAMURA 73
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1
Masaya KOSHIZAKA 77

Proceedings of the 32nd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics
Contents 81
Symposium 2 “Development of Clinical Pharmacological Study Using Human Tissues” 83
Symposium 6 “The Advance of Chronopharmacology” 95
Symposium 15 “Toward Effective Therapeutic Team to Promote Rational Drug Therapy” 105
Symposium 18 “Current Drug Treatment Strategies for Alzheimer's Disease and Parkinson's Disease” 119

Drug Information 33E

Information for Authors 35E

Announcements 37E
Proceedings of the 32nd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

December 1–3, 2011 (Hamamatsu)
President: Hiroshi WATANABE (Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine)

Symposium 2 “Development of Clinical Pharmacological Study Using Human Tissues”
Summary

S2–1 The Human Tissue Bank for Medical Research in St. Marianna University School of Medicine Hospital
Sachiko TAKENOSHITA-NAKAYA 85
S2–2 Possible Role of HAB Research Organization in Human Biomaterial Procurement in Japan Satoshi SUZUKI, et al. 87
S2–3 Providing Human Tissues and Cells for Biomedical Research Takuo KOSAKA 89
S2–4 Development of Exon Skipping Therapy for Duchenne Muscular Dystrophy Using Patient-Derived Cells Takashi SAITO, et al. 91
S2–5 Expression Profile of Cytochrome P450s in the Small Intestine of Japanese Yuko TAKEBA, et al. 93

Symposium 6 “The Advance of Chronopharmacology”
Summary

S6–1 Biological Rhythms and Drug Discovery Shigenobu SHIBATA 97
S6–2 Chronopharmacokinetics Based on Molecular Clock Shigehiro OHDO, et al. 99
S6–3 Biological Rhythm and Drug Adverse Effect Akio FUJIMURA 101
S6–4 Chronotherapy with Antihypertensive Drugs Keiko UEZONO 103

Symposium 15 “Toward Effective Therapeutic Team to Promote Rational Drug Therapy”
Summary

S15–1 Introduction : Trend in Interdisciplinary Approach in Healthcare Policy Junichi KAWAKAMI 107
S15–2 Multidisciplinary Team Approaches and Roles of Pharmacists in Cancer Therapy Tomohiro TERADA, et al. 109
S15–3 Interdisciplinary Approach to Anti-Infectious Pharmacotherapy in the Intensive Care Unit through the Therapeutic Drug Monitoring Takanami NAITO, et al. 111
S15–4 In Case of Clinical Trials Team Toshiko ISHIBASHI 113
S15–5 Promoting Cooperation between Healthcare Professionals and Patients Kyoko KITAZAWA 115
S15–6 Education for Therapeutic Team Members to Promote Rational Drug Therapy Shigeyuki NAKANO 117

Symposium 18 “Current Drug Treatment Strategies for Alzheimer’s Disease and Parkinson’s Disease”
Summary

S18–1 Neurological Disorders : PMDA’s Role in New Product Development Takashi MORITOYO 121
S18–2 Perspectives on the Future Therapeutics of Alzheimer Disease Hiroaki MIYAJIMA 123
S18–3 Strategies of Drug Development for Neurodegenerative Disorders --Development of Antiparkinson Drugs Akihisa MORI 125
S18–4 Current Status and Future Prospects of Antiparkinsonian Agents Masahiro NAGAI 127